Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance

Heron Therapeutics IncTrade
abrdn Physical Palladium Shares ETFTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs abrdn Physical Palladium Shares ETF — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while abrdn Physical Palladium Shares ETF trades at $24.87. The key difference: abrdn Physical Palladium Shares ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

HRTXPALL
Market Cap
$63.41M
Sector
HealthCommodities - Metals/Agriculture
52-Week High
$1.49$37.18
52-Week Low
$0.32$19.96
Enterprise Value
$161.31M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

abrdn Physical Palladium Shares ETF

PALL trades at $25.05, up 0.64% with bullish technical signals from moving averages. The stock recently underwent a 1:5 split on May 18, 2026. Technical indicators show mixed signals with RSI suggesting mild overbought conditions while ADX indicates strong trend strength. Support and resistance levels cluster around $25-$26, creating a key price zone.

PALL presents a contrarian opportunity as palladium prices remain 47% below January 2026 highs. Supply risks and industrial demand support long-term fundamentals, though the ETF faces commodity price volatility and Federal Reserve policy uncertainty as near-term headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About abrdn Physical Palladium Shares ETF

PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.

Read more on PALL